Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.
about
Development of targeted therapies in treatment of glioblastomaHarnessing the apoptotic programs in cancer stem-like cellsCXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion currentGetting to the source: selective drug targeting of cancer stem cells.In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumorsTRIM8 downregulation in glioma affects cell proliferation and it is associated with patients survivalCancer stem cells and chemoresistance: The smartest survives the raidThe role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.Combining molecular targeted agents with radiation therapy for malignant gliomasInhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells.Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cellsHigh expression of leptin receptor leads to temozolomide resistance with exhibiting stem/progenitor cell features in gliobalastoma.Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness.New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells.ABC transporters as differentiation markers in glioblastoma cells.Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737.Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cellsHuman mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?Translational gap in ongoing clinical trials for glioma.Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas.Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability
P2860
Q26778787-7EE2134D-72BE-4F3F-A707-3CE67BCEBF2FQ26801037-B1BED785-892F-4B4E-AD45-6FB0CB9C5A6FQ33677057-09DB33DE-A5E8-4278-9FEE-77C84EF36215Q34957274-DFDBBACF-5272-4669-8142-FDA0EAAEF91EQ35156404-40668D9A-1AA7-4B77-A252-2EF66F8D8380Q35425337-DF9EB226-5BB3-41FD-91A6-B59728C88BB3Q35664663-552B201B-DE38-4570-86F2-A401CD405B15Q36730432-BDB7D681-C9A3-4B04-9434-DECCA558F5E6Q36795940-4702AF8A-EA43-4980-9927-DA3461B2848CQ37099594-589C672D-479D-491D-941B-E75DEA724A29Q37368670-780A389A-81B7-433E-B3DE-23F0A211E93AQ37437614-9D1C4A45-369D-4D74-BADA-B7029BBA687BQ37525858-1B063747-8761-424C-A73D-CBC1F7DB4883Q38183283-FB0917D6-E39E-44C9-ABBF-87B710D20749Q38187997-1BC2FB4D-AE76-405D-91EF-78B07E3EFAFAQ38305765-AD9BF5CB-3BAF-4AB0-BE26-CD6AE7255443Q38786782-9A85F09A-AFF1-4E35-8499-498342586376Q38819651-A8C81DBC-8E41-42D2-A5EA-78FD9663B451Q38860996-2CAA46F5-1356-41F7-ADFF-22BE98DCF535Q39472878-7809E57B-8E67-4FA3-99CC-2054F0ABA65BQ42038363-0395C337-BA0F-443C-9B7D-6A889385563FQ42368133-6D00CEAD-B950-4417-8DB4-A08DAB0C1FD3Q48002716-46A156B7-0763-438C-80BC-C2445A4B74FAQ48116589-3BADE1A1-082E-4161-930B-20DD4334C351Q58728819-21E51ECB-C52D-4FB5-84F4-D4F574C5492D
P2860
Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Sorafenib selectively depletes ...... g cells from primary cultures.
@ast
Sorafenib selectively depletes ...... g cells from primary cultures.
@en
type
label
Sorafenib selectively depletes ...... g cells from primary cultures.
@ast
Sorafenib selectively depletes ...... g cells from primary cultures.
@en
prefLabel
Sorafenib selectively depletes ...... g cells from primary cultures.
@ast
Sorafenib selectively depletes ...... g cells from primary cultures.
@en
P2093
P2860
P50
P356
P1433
P1476
Sorafenib selectively depletes ...... ng cells from primary cultures
@en
P2093
Alessandra Pattarozzi
Daniela Marubbi
Elisa Carra
Roberto E Favoni
P2860
P304
P356
10.4161/CC.23372
P577
2013-01-16T00:00:00Z